AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06644105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefditoren pivoxil tablets
Description: took cefditoren pivoxil tablets 200mg after
Study NCT05176665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB-01
Description: EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
Study NCT06389032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentor Support and Caregiver Education
Description: 12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.
Study NCT06389032 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Mentor Support and Caregiver Education
Description: 12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.
Study NCT06389032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver Education
Description: 12-weeks of receiving weekly curated list of Lewy Body Dementia (LBD) educational resources based on the weekly topics via email.
Study NCT06636578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
Study NCT06636578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: will receive 30 ml of 0.25% of plain ropivacaine for each side.
Study NCT06636578 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: fentanyl
Description: will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
Study NCT06628986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: 20 minutes once a week for 8 weeks
Study NCT06628986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NLP
Description: NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks
Study NCT06628986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control
Description: control group, no practice,
Study NCT05989997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-SNA002
Description: 68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
Study NCT05621837 — intervention group
Intervention type: OTHER
Intervention: MDSC quantification
Description: Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
Study NCT06569316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood or saliva and leftover tissue sample collection
Study NCT06569316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive care plan recommendations
Study NCT06569316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing
Study NCT06569316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06569459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib Injection [Cosela]
Description: Chemoradiotherapy and immunotherapy with Trilaciclib in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
Study NCT06569459 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
Study NCT05054101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Real-time assessment using the VieCovid2020 smartphone application
Description: a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
Study NCT05054101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time assessment using the VieCovid2020 smartphone application
Description: a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
Study NCT05529706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Health Program
Description: The Brain Health Program employs 1-hour/week group-based training and education regarding modifiable Alzheimer's disease dementia risk factors delivered over a 12-week period. Participants will be assigned into a group of up to 20 participants, and participants will engage the Brain Health Program collaboratively, as administered by the program content leader (instructor), while also being monitored and supported by the tech leader (in accordance with the Diabetes Prevention Program model).
Study NCT06297460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systems Training for Emotional Predictability & Problem Solving (STEPPS)
Description: STEPPS is based on a cognitive-behavioral and skills training approach divided into three major components. The first component (sessions: 1-2) teaches participants to replace misconceptions about the presented issues with greater awareness of thoughts, feelings, and behaviors that characterize them. It also helps them identify their own thought patterns driving their behaviors. The second (sessions 3-12) teaches skills to more effectively manage the cognitive and emotional effects of the issues, such as distancing, communication, challenging, distraction, and problem-solving. The third component (sessions 13-19) teaches behavioral skills where participants are encouraged to master habits of healthy eating, sleep hygiene, regular exercise, leisure activities, health monitoring, self-harm prevention, and interpersonal effectiveness. The therapeutic objectives of the three blocks are awareness of illness (1), emotional regulation (2), and behavioral regulation (3).
Study NCT05368519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brijjit®
Description: Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
Study NCT06252415 — intervention group
Intervention type: BIOLOGICAL
Intervention: foetal amniotic fluid sample
Description: At the inclusion visit, during the foetal samples taken for the CMA/ES as part of the care.
Study NCT06252415 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood samples
Description: 2 x 5ml blood EDTA tubes for both parents
Study NCT05981430 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplant
Description: Active comparator will receive infusion of 125mL fecal suspension via enema
Study NCT05981430 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham fecal microbiota transplant
Description: Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
Study NCT06252415 — intervention group
Intervention type: OTHER
Intervention: semi-structured online interviews
Description: 25 included couples will be invited to take part in 2 semi-structured online interviews (by telephone or videoconference)
Study NCT05258292 — intervention group
Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Glucose levels will be measured using continuous glucose monitoring
Study NCT05258292 — intervention group
Intervention type: DRUG
Intervention: Insulin
Description: Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
Study NCT05258292 — intervention group
Intervention type: OTHER
Intervention: Premenstrual symptoms
Description: Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
Study NCT05258292 — intervention group
Intervention type: OTHER
Intervention: Ovulation kits
Description: Ovulation testing will be done using ovulation kits
Study NCT05258292 — intervention group
Intervention type: DEVICE
Intervention: Fitbit Inspire 2
Description: Physical activity will be assessed using the Fitbit Inspire 2
Study NCT05258292 — intervention group
Intervention type: OTHER
Intervention: Keenoa
Description: Food intake will be assessed using the Keenoa phone application
Study NCT05258292 — intervention group
Intervention type: OTHER
Intervention: Menstrual cycle
Description: The application My Calendar will be used to record information on the menstrual cycle
Study NCT05229666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Challenge
Description: Cognitive challenge delivered via computer.
Study NCT06195007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: The motivational interview (MI) is a 10-15 minute patient-centered conversation which will focus on tobacco use. Multiple communication strategies can be employed during the MI, including open-ended questions, affirmative statements, reflective listening, use of a 'confidence ruler', and summarizing. The 'confidence ruler' technique in this patient population involves asking the patient On a scale of zero to ten, how confident are you that you can stop using tobacco?, and then requesting further information about why they selected a certain number. These communication strategies and techniques are designed to uncover and foster a patient's own internal motivations to change the target behavior.
Study NCT05500521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Caloric irrigation
Description: In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.
Study NCT05500521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vHIT
Description: This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.
Study NCT05500521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VEMP
Description: Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
Study NCT06564935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heptaminol Hydrochloride
Description: heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia
Study NCT06564935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
Study NCT01296204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB4 antibody-Iodine 131
Description: Injection of an antibody after labelling with Iodine 131
Study NCT06277050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance Therapy with Toripalimab and Capecitabine
Description: Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
Study NCT06277050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance Therapy with Capecitabine
Description: Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
Study NCT05188014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luteal Phase Aerobic Exercise
Description: Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.
Study NCT05188014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follicular Phase Aerobic Exercise
Description: Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
Study NCT05156528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine
Description: Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.
Study NCT05156528 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intramuscular dose contains 0.15\~0.25 mg of aluminum ion
Study NCT06517953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: An orally first-generation EGFR inhibitior.
Study NCT06517953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib
Description: An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
Study NCT06013345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: analgosedation without secured airway
Study NCT06013345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: analgosedation with secured airway
Study NCT06013345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: TIVA with secured airway
Study NCT04763278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Digit
Description: The Point Digit partial hand prosthetic system consists of 1-4 ratcheting mechanical digits and a mounting bracket
Study NCT06449118 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Stress Reduction Program
Description: Mindfulness based-Stress Reduction Program an 8-week program
Study NCT05870124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nalu Neurostimulation System for PNS
Description: The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
Study NCT05870124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Conventional Medical Management is the best standard of care treatment for the patient
Study NCT06465095 — intervention group
Intervention type: GENETIC
Intervention: Baseline
Description: Measurements and sampling
Study NCT05410223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
Description: Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Study NCT05410223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth
Description: Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Study NCT05410223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline
Description: Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.
Study NCT05410223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth
Description: Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd
Study NCT06555224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systane Hydration MDPF eye drops
Description: Systane Hydration MDPF eye drops 4x daily for 3 months additional to routine medication after cataract surgery
Study NCT05653037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD4059
Description: Subcutaneously Administered RBD4059 in Healthy Subjects.
Study NCT05937854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
Study NCT05937854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one or two encapsulated tablets of placebo po QD
Study NCT05473624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167
Description: Participants will receive HRS-1167.
Study NCT04779008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning （RIPC）
Description: Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
Study NCT05653037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo in Healthys Subject.
Study NCT05256537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omission of the drug mycophenolate mofetil
Description: Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
Study NCT06493526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.
Description: Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
Study NCT05360784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
Description: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Study NCT05360784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
Description: Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Study NCT05938062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)
Description: the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
Study NCT04747080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
Study NCT04747080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone is repeated in the case of lack of response by day 14).
Study NCT04747080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
Study NCT05994365 — intervention group
Intervention type: DRUG
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation.
Study NCT05490407 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
Study NCT06206642 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Low-dose CT images were first collected during scanning. The tube voltage was 120kilovolt, the tube current was 50-220Milliampere and the layer thickness was 3.75mm.